Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat NSCLC and squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS), respectively.
Read the full 376 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD